Cardiolipin is a major membrane
phospholipid in the mitochondria and is essential for cellular energy metabolism mediated through mitochondrial oxidative phosphorylation. Recent studies indicate that it plays a diverse role in cellular metabolism. Eukaryotic
cardiolipin is synthesized de novo from
phosphatidic acid via the cytidine-5'-diphosphate-1,2-diacyl-sn-glycerol pathway and is deacylated to
monolysocardiolipin in order for it to be remodelled into the form that is observed in mitochondrial membranes. This resynthesis of deacylated
cardiolipin from
monolysocardiolipin occurs via the
Barth Syndrome gene product tafazzin and acyllysocardiolipin acyltransferase-1,
monolysocardiolipin acyltransferase-1 and the alpha subunit of trifunctional
protein.
Heart failure is a disease condition in which the amount and type of
cardiolipin is altered. Several animal models have been generated to study the role of altered
cardiolipin in
heart failure. In many of these models loss of the tetralinoleoyl-
cardiolipin species is observed during the development of the
heart failure. In the
doxycycline inducible
short hairpin RNA tafazzin knock down mouse, loss of tetralinoleoyl-
cardiolipin is associated with a mitochondrial bioenergetic disruption. Reduction in mitochondrial supercomplex formation and
NADH dehydrogenase activity within these supercomplexes is observed. Modulation of CL fatty acyl composition may serve as a therapeutic strategy for the treatment of several pathologies including cardiac dysfunction.We propose that increasing
cardiolipin may improve mitochondrial function and potentially serve as a
therapy for diseases which exhibit
mitochondrial dysfunction involving reduced
cardiolipin.